Biotechnology

Biotechnology: gene and cell therapies, gene editing, mRNA, biologics and new drugs, clinical trials and FDA decisions, and the biotech companies and investors behind them, from BioPharma Dive, STAT, GEN and the news, with research from Nature Biotechnology and journals.

STAT Biotech Elaine Chen

STAT+: Most-favored nations policy makes drugmakers rethink launches abroad

Drug companies seem to be looking for workarounds to protect their U.S. sales against Trump's "most-favored nations" policy:

Read at STAT Biotech

BioPharma Dive Kristin Jensen

Drug price hikes in Germany could push US costs higher, study says

The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.

Read at BioPharma Dive

BioPharma Dive BioPharma Dive staff

AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning

The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.

Read at BioPharma Dive

Viet Nam News (state-run daily)

Biotechnology expands prospects for sustainable crop production

In 2024 alone, the global area planted with GM crops reached 218.7 million hectares, an increase of nearly 3.7 million hectares from 2023 and the highest level since the technology was first commercialised.

Read at Viet Nam News (state-run daily)

BioPharma Dive Delilah Alvarado 2 publishers

PepGen soars on promising early data for muscular dystrophy drug

While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.

Read at BioPharma Dive

Also at STAT Biotech

BBC World Geopolitics

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.

Read at BBC World

GEN (Genetic Engineering & Biotechnology News) Sophia Ktori

How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years

Chemotherapy helps many women survive breast cancer, but the results of new research suggest that chemotherapy may also accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes.

Read at GEN (Genetic Engineering & Biotechnology News)

BioPharma Dive Jonathan Gardner

Beam’s base editing therapy for sickle cell hits goal in pivotal trial

The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.

Read at BioPharma Dive

GEN (Genetic Engineering & Biotechnology News) Corinna Singleman, PhD

From Farm Waste to Medical Nanoparticles

Fruit peels, rice husks, and other crop leftovers can yield biomedical nanoparticles, but variable feedstocks, scale-up hurdles, and thin safety data still stand between lab promise and reliable commercial bioprocessing.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Corinna Singleman, PhD

Hybrid Model Captures Lactate Run-Away and Back-Metabolism

A hybrid model provides hard-to-achieve insights into lactate performance during bioprocessing, creating conditions for more accurate predictions to better manage key batch parameters and variability.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Corinna Singleman, PhD

Extracellular Vesicle Product Developer Creates Potency Assay

A company developing extracellular vesicle-based products has developed a potency assay for quality control. They hope to adapt it for future products and scale it to commercial manufacturing.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Corinna Singleman, PhD

Automation a Path to Lower Cell Therapy Costs

Australian developer Currus Bio predicts that automating the production of its candidate cancer cell therapy, CUR-001, using the Cocoon platform will reduce costs and enhance its ability to scale production as the product moves through trials.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Alex Philippidis

Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition

The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases.

Read at GEN (Genetic Engineering & Biotechnology News)

Ars Technica Beth Mole 3 publishers

FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss

The risk appears small and data is mixed, but FDA wants patients to be aware.

Read at Ars Technica

Also at CBS News, STAT Biotech

STAT Biotech Elaine Chen

STAT+: GLP-1s are given an FDA warning for rare eye condition risk

The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”

Read at STAT Biotech

The Guardian US Julia Kollewe

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned. GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a…

Read at The Guardian US

VnExpress International

Vietnamese hospital receives Japanese cell therapy technology for cancer and chronic disease treatment

Tam Anh General Hospital has completed an exclusive technology transfer from Japan's Grandsoul Medical Group covering immune cell and stem cell technologies being explored for treatment of cancer and chronic diseases.

Read at VnExpress International

BioPharma Dive Gwendolyn Wu

London biotech Oyster harvests $60M for tau-targeting brain drugs

Oyster says a tweak it's made to traditional protein degrading technology can help break down tau, which has long been a focus of Alzheimer’s drug research.

Read at BioPharma Dive

BioPharma Dive Gwendolyn Wu

BIO unveils plan for US to remain biotech’s ‘global leader’

A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.

Read at BioPharma Dive

South China Morning Post Xinmei Shen Geopolitics

Chinese biotech giant WuXi AppTec’s shares jump after Pentagon blacklist reversal

WuXi AppTec’s shares jumped on Tuesday after the Pentagon removed the company from a list of entities allegedly linked to the Chinese military, marking a win for the biotech service giant and raising hopes among other mainland firms…

Read at South China Morning Post

GEN (Genetic Engineering & Biotechnology News) Savannah Wiegel

Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research

Illumina has announced an early access program to a duplex sequencing workflow that reads both DNA strands to detect trace ctDNA in molecular residual disease and tumor evolution studies. Kits are expected in early 2027.

Read at GEN (Genetic Engineering & Biotechnology News)

BioPharma Dive Jacob Bell

Bayer wins FDA nod for a new kind of blood thinner

Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.

Read at BioPharma Dive

STAT Biotech Elaine Chen and Elizabeth Cooney

STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

Bayer's drug is the first in a novel class of medications designed to prevent blood clots without increasing risk of bleeding.

Read at STAT Biotech

GEN (Genetic Engineering & Biotechnology News) Sophia Ktori

How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome

A study showed how E2F1 can trigger cell division without having to unpack the cell’s genetic material. Instead, it takes a shortcut path by binding directly to a small area of the DNA that remains tightly packaged inside the cell.

Read at GEN (Genetic Engineering & Biotechnology News)

BioPharma Dive Delilah Alvarado

Vir hepatitis D drug succeeds in first pivotal study

A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.

Read at BioPharma Dive

BioPharma Dive Jacob Bell

Argenx to buy peptide platform in potentially billion-dollar deal

For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.

Read at BioPharma Dive

BioPharma Dive Sy Mukherjee

Ramaswamy’s biotech baggage haunted his political run

A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

Read at BioPharma Dive

STAT Biotech Meghana Keshavan and Brittany Trang

STAT+: Gene therapy’s long-debated cancer risk materializes

For years, gene therapy researchers debated whether the viruses they use to ferry replacement genes into cells could cause tumors. A small number of cases now offer strong evidence that…

Read at STAT Biotech

GEN (Genetic Engineering & Biotechnology News) Uduak Thomas

Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests

Childhood cancers may not always need extra mutations to spread, a new review study indicates. Instead, developmental plasticity may let tumor cells shape-shift into states that help them grow, resist treatment, and ultimately metastasize.

Read at GEN (Genetic Engineering & Biotechnology News)

GEN (Genetic Engineering & Biotechnology News) Kathy Vuksanaj

New AI Models Are Turbo-Charging Protein Design

Computer-designed protein therapeutics move from proof-of-concept to wet-lab validation and even clinical trials as the field heats up.

Read at GEN (Genetic Engineering & Biotechnology News)

Older stories